Literature DB >> 15027564

Methadone-related deaths in Palm Beach County.

Barbara C Wolf1, Wendy A Lavezzi, Linda M Sullivan, Lisa M Flannagan.   

Abstract

The authors reviewed cases investigated by the Palm Beach Medical Examiner's Office in which postmortem toxicologic studies indicated the presence of methadone over the period from 1998 to 2002, to examine the role of the drug in these deaths. There were 139 methadone-positive cases, including 75 in which the death was attributed to combined drug toxicity and 23 to methadone toxicity alone. Methadone was most frequently used in conjunction with other prescription or illicit drugs, most commonly benzodiazepines and/or cocaine. There was considerable overlap in the postmortem blood methadone concentrations among the groups. Concentrations ranged from 0.114 mg/L-1.939 mg/L (mean .0559 mg/L) in cases where death was attributed to methadone toxicity; 0.050 mg/L-1.903 mg/L (mean 0.411 mg/L) in cases of combined drug toxicity; 0.069 mg/L-0.644 mg/L (mean 0.224 mg/L) in deaths attributed to other drugs; 0.062 mg/L-1.090 mg/L (mean 0.344 mg/L) among deaths attributed to natural causes and 0.072 mg/L-2.7 mg/L (mean 0.605 mg/L) among deaths due to trauma. The concentrations of methadone detected indicate that it may not be possible to establish a lethal methadone range because some deaths occurred at methadone concentrations below previously reported lethal ranges, and because of the presence of other drugs. Determining the cause of death in methadone-positive cases necessitates correlation with autopsy results and investigative findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15027564

Source DB:  PubMed          Journal:  J Forensic Sci        ISSN: 0022-1198            Impact factor:   1.832


  16 in total

1.  Trends in methadone-related deaths in Zurich.

Authors:  Patrick Johannes Laberke; Christine Bartsch
Journal:  Int J Legal Med       Date:  2010-03-27       Impact factor: 2.686

Review 2.  Determinants of increased opioid-related mortality in the United States and Canada, 1990-2013: a systematic review.

Authors:  Nicholas B King; Veronique Fraser; Constantina Boikos; Robin Richardson; Sam Harper
Journal:  Am J Public Health       Date:  2014-06-12       Impact factor: 9.308

Review 3.  Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system.

Authors:  Michelle A Patriquin; Isabelle E Bauer; Jair C Soares; David P Graham; David A Nielsen
Journal:  Psychiatr Genet       Date:  2015-10       Impact factor: 2.458

4.  The source of methadone in overdose deaths in Western Virginia in 2004.

Authors:  Melissa B Weimer; P Todd Korthuis; George S Behonick; Martha J Wunsch
Journal:  J Addict Med       Date:  2011-09       Impact factor: 3.702

5.  Methadone and methadone metabolites in postmortem specimens.

Authors:  Terry J Danielson; Ashraf Mozayani; Luis A Sanchez
Journal:  Forensic Sci Med Pathol       Date:  2008-05-30       Impact factor: 2.007

6.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

7.  Opioid deaths in rural Virginia: a description of the high prevalence of accidental fatalities involving prescribed medications.

Authors:  Martha J Wunsch; Kent Nakamoto; George Behonick; William Massello
Journal:  Am J Addict       Date:  2009 Jan-Feb

8.  Parent and Metabolite Opioid Drug Concentrations in Unintentional Deaths Involving Opioid and Benzodiazepine Combinations.

Authors:  Marcia D Fields; Marie A Abate; Lan Hu; D Leann Long; Matthew L Blommel; Nabila A Haikal; James C Kraner
Journal:  J Forensic Sci       Date:  2015-07       Impact factor: 1.832

Review 9.  Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use.

Authors:  Jeffrey A Gudin; Shanthi Mogali; Jermaine D Jones; Sandra D Comer
Journal:  Postgrad Med       Date:  2013-07       Impact factor: 3.840

10.  ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.

Authors:  Catherine J Spellicy; Thomas R Kosten; Sara C Hamon; Mark J Harding; David A Nielsen
Journal:  Pharmacogenet Genomics       Date:  2013-07       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.